alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Case No. 14,780.

#### UNITED STATES v. CHANA.

[Hoff. Land Cas. 155.] 1

District Court, N. D. California.

June Term, 1856.2

Mexican Land Grant — Sutter General Title.

The validity of claims under the Sutter general title affirmed in U. S. v. Hensley [unreported].

| Reversed by the supreme court. See 24 How. pió U. S.) 131.]

Claim [by Claude Chana] for four leagues of land in Yuba county [the Rancho Nemshas], confirmed by the board, and appealed by the United States.

William Blanding, U. S. Atty.

Thornton & Williams, for appellee.

1

 [Reported by Nurna Hubert, Esq., and bere reprinted by permhsioL.]

2

 [Reversed in 24 How. (65 U. S.) 131.]

HOFFMAN, District Judge.

The claim in this case rests upon what is known as the “general title” of Governor’ Micheltorena. The validity of that title has already been affirmed by this court in the case of U. S. v. Hensley; and the only inquiries that arise are whether the person from whom the claimant derives title was one of those for whose benefit the title issued—whether he has performed the conditions, and whether the land intended to be granted is sufficiently indicated. On the first point the evidence leaves no room for doubt. The documents contained in the ex-pediente and the evidence on file clearly show that Pedro Teodoro Sicard was one of those who petitioned the governor, on whose applications Gen. Sutter had reported favorably, and for whose benefit the general title issued and was delivered to the latter. The copy of the general title which Gen. Sutter delivered to each petitioner in whose favor it had issued is produced, with the certificate of Sutter showing it to be a copy of the original. The board does not seem to have entertained any doubt as to the fact that Sicard was intended to be one of the grantees under the general title. The evidence also shows that the conditions of occupation and cultivation were fully complied with, and the situation and boundaries of the land are indicated with great precision in the petition and diseño which accompanies it. • The claim was confirmed by the board, and the case has been submitted without argument or objection on the part of the United States to its validity.

We are of opinion that a decree affirming the decision of the board should be entered.
#### David D. Acker and others, Appellants, v. Charles E. Leland and others, Respondents.

Judgment affirmed, with costs. Opinion by

Bockes. J.
Before the Third Division,

August 8, 1966

No. P66/182. —

#### United China & Glass Company *v.*United States, protests 65/9890 and 65/12373 (Philadelphia).

LaNdis, J.

In accordance with stipulation of counsel that the merchandise covered by the foregoing protests consists of cups and saucers similar in all material respects to those the subject of *W. Kay Company, Inc.*v. *United States*(53 Cust. Ct. 130, C.D. 2484), the claim of the plaintiff was sustained.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Transition to Independence Study Section.                    

*Date:*                         November 16-17, 2023.                    

*Time:*                         8:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         The Canopy by Hilton Washington DC Bethesda North, 940 Rose Avenue, North Bethesda, MD 20892 (Hybrid Meeting).                    

*Contact Person:*                         Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 205-H, Bethesda, MD 20892, (301) 827-7969,                         *Pintuccig@nhlbi.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 18, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-20649 Filed 9-22-23; 8:45 am]

BILLING CODE 4140-01-P
From: bruce@poormans.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 2:12:43 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Although not employed by my church, I am an elder of our church and strongly object to the deceptive

way the law pays for abortion and related devices and further my insurance will go higher to cover the

mandate.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Bruce Brotnov

Lewiston, ID 83501
#### Abel A. Crosby v. The President, etc., of the Delaware and Hudson Canal Company.

Motion for leave to go to Court of Appeals granted.
From: cjwehrman@comcast.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 2:51:23 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

Carol Wehrman

, 55442-1511
The Honorable Mary Ann L. Medler, United States Magistrate Judge for the

1

Eastern District of Missouri, to whom the case was referred for final disposition by

consent of the parties pursuant to 28 U.S.C. § 636(c). 

United States Court of Appeals

FOR THE EIGHTH CIRCUIT

___________

No. 98-2081

___________

Monty Ross, *

 *

Appellant, *

 * Appeal from the United States

v. * District Court for the

 * Eastern District of Missouri. 

Joel Bautista, M.D.; Correctional *

Medical Services, * [UNPUBLISHED]

 *

Appellees. *

___________

 Submitted: August 31, 1998

 Filed: September 4, 1998

___________

Before FAGG, BEAM, and LOKEN, Circuit Judges.

___________

PER CURIAM.

Monty Ross, a Missouri prisoner, appeals from the district court&s adverse grant 1

of summary judgment in this 42 U.S.C. § 1983 action. We have carefully reviewed the

record and the parties& briefs, and affirm the judgment of the district court for the

reasons set forth in its memorandum. See 8th Cir. R. 47B.
-2-

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
Before the First Division,

February 2, 1956

No. 59702.

#### H. S. Import Co., Inc. *v.*United States,

protest 248692-K (New York).

*335Opinion by

Oliver, C. J.

In accordance with stipulation of counsel that the merchandise consists of opaque white glass stones of different sizes and shapes, faceted, similar in all material respects to those the subject of Abstract 59105, the claim of the plaintiff was sustained.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                     148,815,950
<SECURITIES>                                         0
<RECEIVABLES>                               86,628,102
<ALLOWANCES>                               (2,593,623)
<INVENTORY>                                  8,460,184
<CURRENT-ASSETS>                           279,426,795
<PP&E>                                     381,902,200
<DEPRECIATION>                            (84,654,995)
<TOTAL-ASSETS>                           2,547,723,776
<CURRENT-LIABILITIES>                      173,841,530
<BONDS>                                  1,513,941,061
<PREFERRED-MANDATORY>                      502,975,398
<PREFERRED>                                          0
<COMMON>                                        93,271
<OTHER-SE>                                 165,883,615
<TOTAL-LIABILITY-AND-EQUITY>             2,547,723,776
<SALES>                                     17,950,047
<TOTAL-REVENUES>                           377,759,956
<CGS>                                       33,838,918
<TOTAL-COSTS>                              347,423,237
<OTHER-EXPENSES>                           (7,496,964)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                         107,377,903
<INCOME-PRETAX>                          (103,684,674)
<INCOME-TAX>                              (27,834,289)
<INCOME-CONTINUING>                       (75,850,385)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                           (20,387,134)
<CHANGES>                                            0
<NET-INCOME>                              (96,237,519)
<EPS-BASIC>                                     (2.33)
<EPS-DILUTED>                                   (2.33)


</TABLE>
# (UP

. October 29, 2009 

## 0° °40'1 -? Director, Chemical Control Division (7405M) Room 4146 EPA East U .S. Environmental Protection Agency 1201 Constitution Avenue, NW Washington, DC 20004 202-564-4760 Attn:

Re: ~` ~" `? 

## 6= 0 1 DuPont Corporate Remediation Group Chestnut Run Plaza, Building 715 4417 Lancaster Pike Wilmington, DE 19805 Document Control Office Office of Pollution Prevention and Toxics EPA East, Room

6428 U.S. Environmental Protection Agency 1201 Constitution Avenue, NW Washington, DC 20004 202-564-8930 EPA Docket IDNumber OPPT-2004-0113 Memorandum

of Understanding (MOU) between the U.S. Environmental Protection Agency (EPA) and E. I . DuPont de Nemours and Company (DuPont) for a Perfluorooctanoic Acid (PFOA) Site-Related Environmental Assessment Program (November 3, 2005) Quarterly MOU Status Report #16, Phase II Monitoring/Sampling Work Plan, DuPont Washington Works (October 29, 2009) Dear Sir/Madam

: This Quarterly MOU Status Report #16 is submitted in accordance with Section V .B .3 ofthe above-identified MOU

. All Phase II Work Plan related activities have been completed and the Assessments, required under Section V . D ., have been submitted to EPA. In addition, the Peer Consultation Process (PCP) required under Section V.E.2 ofthe MOU is currently underway. Data reported in this quarterly MOUstatus report were received by DuPont as of November 23, 2009, are not part ofthe Phase II MOUmonitoring activities, but provided by DuPont for completeness of study. An index of this status report is provided as an Attachment to this letter. Ifyou need any additional information or finther clarification, please contact me (302-999-6197) or David W

. Boothe (302-999-4091) .

Andrew S. Hartten Project Director Attachment : Enclosures: Index ofreport documents (1 pfge)

1 paper copy ofthe Quarterly MOUStatus Report #16 - October 29, 2009 1 digital copy ofthe Quarterly MOU Status Report #16 - October 29, 2009



# CONTAINS NO CBI 4-4~

EI . du Pont do Nomoun andCaaOany 

# 3a-a 437Docket No. OPPT-2004-0113 October 29, 2009 EPA-DuPont MOU Index

Final Analvtical Sampl ine Results - Ouarte rly MOUStatus Reao rt #16 Document/Report Ti tle-Pauer Copy No . of Paees* 1 paper copy of the Quarterly MOUStatus Report #16, 192 pages Phase 11 Monitoring/Sampling Work Plan, DuPont Washington Works (OPPT-2004-0113 PFOA Site-Related Environmental Assessment Program) Document/Report Title-Electronic Couy No. of Pages CD 1 of 1 containing the Quarterly MOUStatus Report #16, 190 pages total Phase 11 Monitoring/Sampling Work Plan, DuPont Washington Works (OPPT-2004-0113 PFOA Site-Related Environmental Assessment Program) as one PDF file titled, Quarterly MOU Status Report #16 102909.PDF

Page 2 of 2 OPPT-2004-0113 PFOA Site-Related Environmental Assessment Program
[Federal Register Volume 88, Number 179 (Monday, September 18, 2023)]
[Notices]
[Page 63967]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20059]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Nursing Research; Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Nursing Research 
Initial Review Group.
    Date: October 19, 2023.
    Time: 9:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Nursing Research, 6701 Democracy 
Boulevard, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Weiqun Li, MD, Scientific Review Officer, 
National Institute of Nursing Research, National Institutes of 
Health, 6701 Democracy, Suite 710, Bethesda, MD 20892, (301) 594-
5966, <a href="/cdn-cgi/l/email-protection#22554e4b624f434b4e0c4c4b4a0c454d54"><span class="__cf_email__" data-cfemail="ee998287ae838f8782c0808786c0898198">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, 
Nursing Research, National Institutes of Health, HHS)

    Dated: September 12, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20059 Filed 9-15-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 99.01

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                               SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of The Players Network (the
"Company") on Form 10-QSB for the period ended March 31, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

         (1)      The Report fully  complies  with the  requirements  of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information  contained in the Report fairly  presents,  in
                  all material respects,  the financial condition and results of
                  operations of the Company.

May _____, 2003                                      By: /s/ Mark Bradley
                                                     ---------------------------
                                                     Mark Bradley
                                                     Chief Executive Officer
No. 5.

#### National Association for the Advancement of Colored People *v.*Gray, Attorney General of Virginia, et al.

*Robert L. Carter*on the motion.

Certiorari, 365 U. S. 842, to the Supreme Court of Appeals of Virginia. Argued November 8, 1961. Restored to the calendar for reargument, 369 U. S. 833. The motion to substitute Robert Y. Button et al. in the place of Frederick T. Gray et al. as parties respondent is granted.
No. 310, Misc.

#### Arthur *v.*Director, Patuxent Institution, et al.

Court of Appeals of Maryland. Certiorari denied.
No. 63754.

protest 59/18389 (New York).

#### Ross Products, Inc. *v.*United States,

Opinion by

Oliver, C. J.

In accordance with stipulation of counsel that the merchandise consists of sponges similar in all material respects to those the •subject of Abstract 61191, the claim of the plaintiff was sustained.
Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER I, Matthew J.
Pfeffer, certify that: 1.
I have
  reviewed this quarterly report on Form 10-Q of VaxGen, Inc.2.
Based on my
  knowledge, this report does not contain any untrue statement of a material
  fact or omit to state a material fact necessary to make the statements made,
  in light of the circumstances under which such statements were made, not
  misleading with respect to the period covered by this report;3.
Based on my
  knowledge, the financial statements, and other financial information included
  in this report, fairly present in all material respects the financial
  condition, results of operations and cash flows of the registrant as of, and
  for, the periods presented in this report;4.
The
  registrants other certifying officer and I are responsible for establishing
  and maintaining disclosure controls and procedures (as defined in Exchange
  Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:(a) Designed
  such disclosure controls and procedures, or caused such disclosure controls
  and procedures to be designed under our supervision, to ensure that material
  information relating to the registrant, including its consolidated subsidiaries,
  is made known to us by others within those entities, particularly during the
  period in which this report is being prepared;(b)
  [Reserved];(c)
  Evaluated the effectiveness of the registrants disclosure controls and
  procedures and presented in this report our conclusions about the
  effectiveness of the disclosure controls and procedures, as of the end of the
  period covered by this report based on such evaluation; and(d)
  Disclosed in this report any change in the registrants internal control over
  financial reporting that occurred during registrants most recent fiscal
  quarter (the registrants fourth quarter in the case of an annual report)
  that has materially affected, or is reasonably likely to materially affect,
  the registrants internal control over financial reporting; and5.
The
  registrants other certifying officer and I have disclosed, based on our most
  recent evaluation of internal control over financial reporting, to the
  registrants auditors and the audit committee of registrants board of
  directors (or persons performing the equivalent functions):(a) All
  significant deficiencies and material weaknesses in the design or operation
  of internal control over financial reporting which are reasonably likely to
  adversely affect the registrants ability to record, process, summarize and
  report financial information; and(b) Any
  fraud, whether or not material, that involves management or other employees
  who have a significant role in the registrants internal control over financial
  reporting. February 6, 2007 /s/ Matthew J. PfefferChief Financial Officer - 1 -